ImmunoPrecise Antibodies (IPA) Competitors $0.60 -0.05 (-8.20%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$0.66 +0.06 (+9.59%) As of 09:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPA vs. CABA, IMAB, SAVA, CRDL, KRRO, VIRI, VXRT, ADAG, ORMP, and OPTNShould you be buying ImmunoPrecise Antibodies stock or one of its competitors? The main competitors of ImmunoPrecise Antibodies include Cabaletta Bio (CABA), I-Mab (IMAB), Cassava Sciences (SAVA), Cardiol Therapeutics (CRDL), Korro Bio (KRRO), Virios Therapeutics (VIRI), Vaxart (VXRT), Adagene (ADAG), Oramed Pharmaceuticals (ORMP), and OptiNose (OPTN). These companies are all part of the "pharmaceutical products" industry. ImmunoPrecise Antibodies vs. Its Competitors Cabaletta Bio I-Mab Cassava Sciences Cardiol Therapeutics Korro Bio Virios Therapeutics Vaxart Adagene Oramed Pharmaceuticals OptiNose Cabaletta Bio (NASDAQ:CABA) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, community ranking, media sentiment, earnings, dividends and risk. Which has more risk & volatility, CABA or IPA? Cabaletta Bio has a beta of 2.81, meaning that its stock price is 181% more volatile than the S&P 500. Comparatively, ImmunoPrecise Antibodies has a beta of 0.12, meaning that its stock price is 88% less volatile than the S&P 500. Do analysts recommend CABA or IPA? Cabaletta Bio currently has a consensus price target of $20.33, suggesting a potential upside of 1,061.90%. ImmunoPrecise Antibodies has a consensus price target of $4.00, suggesting a potential upside of 566.22%. Given Cabaletta Bio's higher possible upside, equities research analysts clearly believe Cabaletta Bio is more favorable than ImmunoPrecise Antibodies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cabaletta Bio 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00ImmunoPrecise Antibodies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, CABA or IPA? ImmunoPrecise Antibodies has higher revenue and earnings than Cabaletta Bio. Cabaletta Bio is trading at a lower price-to-earnings ratio than ImmunoPrecise Antibodies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCabaletta BioN/AN/A-$67.68M-$2.54-0.69ImmunoPrecise Antibodies$24.00M1.14-$20.13M-$1.16-0.52 Do insiders and institutionals have more ownership in CABA or IPA? 6.7% of ImmunoPrecise Antibodies shares are owned by institutional investors. 11.3% of Cabaletta Bio shares are owned by company insiders. Comparatively, 6.8% of ImmunoPrecise Antibodies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer CABA or IPA? Cabaletta Bio received 83 more outperform votes than ImmunoPrecise Antibodies when rated by MarketBeat users. However, 88.24% of users gave ImmunoPrecise Antibodies an outperform vote while only 73.13% of users gave Cabaletta Bio an outperform vote. CompanyUnderperformOutperformCabaletta BioOutperform Votes9873.13% Underperform Votes3626.87% ImmunoPrecise AntibodiesOutperform Votes1588.24% Underperform Votes211.76% Is CABA or IPA more profitable? Cabaletta Bio has a net margin of 0.00% compared to ImmunoPrecise Antibodies' net margin of -114.50%. Cabaletta Bio's return on equity of -50.10% beat ImmunoPrecise Antibodies' return on equity.Company Net Margins Return on Equity Return on Assets Cabaletta BioN/A -50.10% -45.49% ImmunoPrecise Antibodies -114.50%-73.74%-42.68% Does the media prefer CABA or IPA? In the previous week, Cabaletta Bio had 14 more articles in the media than ImmunoPrecise Antibodies. MarketBeat recorded 17 mentions for Cabaletta Bio and 3 mentions for ImmunoPrecise Antibodies. Cabaletta Bio's average media sentiment score of 0.63 beat ImmunoPrecise Antibodies' score of 0.29 indicating that Cabaletta Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 2 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunoPrecise Antibodies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCabaletta Bio beats ImmunoPrecise Antibodies on 10 of the 17 factors compared between the two stocks. Get ImmunoPrecise Antibodies News Delivered to You Automatically Sign up to receive the latest news and ratings for IPA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IPA vs. The Competition Export to ExcelMetricImmunoPrecise AntibodiesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.48M$6.85B$5.57B$8.63BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-0.778.7827.1420.06Price / Sales1.14255.64411.98157.10Price / CashN/A65.8538.2534.64Price / Book0.656.557.064.70Net Income-$20.13M$143.93M$3.23B$247.88M7 Day Performance-14.23%3.84%2.85%2.63%1 Month Performance33.39%11.20%9.06%6.36%1 Year Performance-42.27%4.18%31.43%14.05% ImmunoPrecise Antibodies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IPAImmunoPrecise Antibodies2.5434 of 5 stars$0.60-8.2%$4.00+566.2%-41.1%$27.48M$24.00M-0.7780Short Interest ↑CABACabaletta Bio2.9095 of 5 stars$2.06+10.2%$20.33+887.1%-84.2%$104.53MN/A-0.9650Trending NewsAnalyst ForecastAnalyst RevisionGap DownIMABI-Mab3.2194 of 5 stars$1.28-2.3%$5.50+329.7%+33.9%$104.53M$3.27M0.00380News CoveragePositive NewsGap UpSAVACassava Sciences4.2849 of 5 stars$2.13+6.0%$54.50+2,458.7%-88.9%$102.90MN/A-1.5430Positive NewsCRDLCardiol Therapeutics2.3554 of 5 stars$1.24-0.8%$8.67+598.9%-51.0%$102.44MN/A-3.1820KRROKorro Bio3.5683 of 5 stars$10.80-5.4%$102.43+848.4%-64.8%$101.42M$4.82M-1.1470Positive NewsAnalyst RevisionGap UpHigh Trading VolumeVIRIVirios TherapeuticsN/A$5.18-2.1%$3.00-42.1%+2,104.8%$99.76MN/A-19.195VXRTVaxart2.1228 of 5 stars$0.45+3.9%$3.00+566.7%-34.5%$98.84M$47.40M-1.10120Gap UpADAGAdagene2.7362 of 5 stars$2.09+7.5%$8.00+283.7%-32.0%$98.22M$103.20K0.00260Positive NewsORMPOramed Pharmaceuticals1.8546 of 5 stars$2.38+1.7%N/A+7.7%$97.22M$2M21.6410Positive NewsOPTNOptiNose1.8144 of 5 stars$9.60flat$9.00-6.3%N/A$97.22M$81.86M-2.29190 Related Companies and Tools Related Companies Cabaletta Bio Alternatives I-Mab Alternatives Cassava Sciences Alternatives Cardiol Therapeutics Alternatives Korro Bio Alternatives Virios Therapeutics Alternatives Vaxart Alternatives Adagene Alternatives Oramed Pharmaceuticals Alternatives OptiNose Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IPA) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoPrecise Antibodies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunoPrecise Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
